GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+12.02%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$303M
AUM Growth
+$303M
(-5.2%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-7.06%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
69
New
16
Increased
8
Reduced
15
Closed
10
Top Buys
| 1 |
ALLK
Allakos
ALLK
|
$9M |
| 2 |
GH Research
GHRS
|
$8.82M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$6.73M |
| 4 |
Leap Therapeutics
LPTX
|
$6.62M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$6.59M |
Top Sells
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$12.1M |
| 2 |
Biogen
BIIB
|
$11.3M |
| 3 |
RAPT Therapeutics
RAPT
|
$9.94M |
| 4 |
Fate Therapeutics
FATE
|
$8M |
| 5 |
TG Therapeutics
TGTX
|
$6.98M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $19.1M | 5.59% | 120,000 -15,000 | -11% | -$2.39M |
|
2
Iovance Biotherapeutics
IOVA
$807M
| $17.3M | 5.05% | 700,000 +250,000 | +56% | +$6.17M |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $13.8M | 4.03% | 255,000 -30,000 | -11% | -$1.62M |
|
4
Cogent Biosciences
COGT
$1.69B
| $12.6M | 3.69% | 1,500,000 -100,000 | -6% | -$841K |
|
5
Arvinas
ARVN
$568M
| $12.3M | 3.6% | 150,000 -55,000 | -27% | -$4.52M |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $12.1M | 3.53% | 790,000 -60,000 | -7% | -$917K |
|
|
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11.8M | 3.44% | 725,000 | – | – |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $11M | 3.21% | 575,000 -300,000 | -34% | -$5.73M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.6M | 3.1% | 60,000 +10,000 | +20% | +$1.77M |
|
|
10
Rocket Pharmaceuticals
RCKT
$354M
| $10.5M | 3.06% | 350,000 +225,000 | +180% | +$6.73M |
|
|
ALLK
11
DELISTED
Allakos
ALLK
| $9M | 2.63% | +85,000 | New | +$9M |
|
|
12
GH Research
GHRS
$837M
| $8.82M | 2.58% | +400,000 | New | +$8.82M |
|
13
Kura Oncology
KURA
$686M
| $7.96M | 2.33% | 425,000 -275,000 | -39% | -$5.15M |
|
|
14
RAPT Therapeutics
RAPT
$188M
| $7.76M | 2.27% | 250,000 -320,000 | -56% | -$9.94M |
|
|
15
Leap Therapeutics
LPTX
$12M
| $6.62M | 1.93% | +1,650,000 | New | +$6.62M |
|
|
16
Apellis Pharmaceuticals
APLS
$3.48B
| $6.59M | 1.93% | +200,000 | New | +$6.59M |
|
17
Aldeyra Therapeutics
ALDX
$351M
| $6.15M | 1.8% | 700,000 +100,000 | +17% | +$878K |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $5.76M | 1.68% | 350,000 | – | – |
|
19
VistaGen Therapeutics
VTGN
$102M
| $5.48M | 1.6% | 2,000,000 | – | – |
|
20
Atea Pharmaceuticals
AVIR
$267M
| $5.26M | 1.54% | +150,000 | New | +$5.26M |
|
21
Relmada Therapeutics
RLMD
$37.2M
| $5.24M | 1.53% | +200,000 | New | +$5.24M |
|
22
Aclaris Therapeutics
ACRS
$209M
| $4.95M | 1.45% | 275,000 +25,000 | +10% | +$450K |
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.94M | 1.45% | 500,000 | – | – |
|
|
CTIC
24
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $4.72M | 1.38% | 1,600,000 | – | – |
|
25
Praxis Precision Medicines
PRAX
$958M
| $4.62M | 1.35% | +250,000 | New | +$4.62M |
|